GAULT CHERYL (Chief Operating Officer) sold 6.3% of their position (10K shares) of RAPPORT THERAPEUTICS, INC. on the open market
Open‑market sale worth $415.8K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 7/1/2026ACC: 0001193125-26-292546
Officer· Chief Operating Officer
Since Mar 2026
-10K
Net shares
Net seller
$415.8K
Total sold
4
Open market trades
0B · 4S
4
Total transactions
10K disposed
Non-Derivative Transactions4
Common Stock
Direct
Shares
−1.90K
Price / share
$40.09
Trade value
$76.17K
% of position
1.2%
6/30/2026
159.91K→158.01K
Common Stock
Direct
Shares
−3.79K
Price / share
$41.39
Trade value
$156.96K
% of position
2.4%
6/30/2026
158.01K→154.22K
Common Stock
Direct
Shares
−3.31K
Price / share
$42.17
Trade value
$139.51K
% of position
2.1%
6/30/2026
154.22K→150.91K
Common Stock
Direct
Shares
−1K
Price / share
$43.15
Trade value
$43.15K
% of position
0.7%
6/30/2026
150.91K→149.91K
Total
Net shares
−10K
Net value
-$415.80K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/30/2026 | S · Sale | −1.90K | $40.09 | $76.17K | 1.2% | 159.91K | 158.01K |
| Common Stock Direct | 6/30/2026 | S · Sale | −3.79K | $41.39 | $156.96K | 2.4% | 158.01K | 154.22K |
| Common Stock Direct | 6/30/2026 | S · Sale | −3.31K | $42.17 | $139.51K | 2.1% | 154.22K | 150.91K |
| Common Stock Direct | 6/30/2026 | S · Sale | −1K | $43.15 | $43.15K | 0.7% | 150.91K | 149.91K |
| Total | −10K | -$415.80K | ||||||
Derivative Transactions0
No derivative transactions reported